Got it — I'll add a methodological checkpoints section using your cohort numbers (n=45; 12 recurrence / 33 no recurrence; whole-tumor segmentation masks). Here's a section you can drop into your notebook, with the reasoning behind each checkpoint so you can adjust anything that doesn't match your actual pipeline.

```markdown
## Methodological Checkpoints

This section documents key methodological decisions and validation checks for the
TNBC recurrence prediction model, given the cohort characteristics below.

### Cohort summary
- **Total patients:** 45
- **Recurrence:** 12 (26.7%)
- **No recurrence:** 33 (73.3%)
- **Segmentation:** whole-tumor masks (single ROI per patient, no sub-region
  parcellation)

### Checkpoint 1: Class imbalance is real but not extreme
A 12/33 split (~1:2.75) is imbalanced but not severe. Before reaching for SMOTE
or other synthetic oversampling, confirm:
- [ ] Baseline accuracy of a majority-class classifier (predict "no recurrence"
  for everyone) is reported as a reference point — here that's 73.3%, so accuracy
  alone is a misleading metric for this model.
- [ ] Primary evaluation metric is **not** raw accuracy. Use balanced accuracy,
  AUROC, AUPRC (more informative than AUROC under imbalance), F1, or sensitivity/
  specificity reported together.
- [ ] If class weighting is used (e.g., `class_weight='balanced'`), document the
  weighting scheme rather than silently oversampling.

### Checkpoint 2: Sample size constrains model complexity
With only 12 positive cases, this is a small-n, high-dimensional-features
problem (especially if you're extracting more than a handful of radiomic
features per patient). Checkpoints:
- [ ] Number of features going into the model is reported, and there's an
  explicit feature-selection or dimensionality-reduction step *before* model
  fitting — not after looking at outcomes on the full set.
- [ ] Feature selection is performed **inside** the cross-validation loop
  (nested CV or pipeline-based selection), not on the full dataset beforehand,
  to avoid leakage that inflates performance.
- [ ] A rule of thumb such as "no more than ~1 feature per 10-15 events" (i.e.,
  roughly 1-2 features given 12 recurrence events) is noted as a target or
  explicitly justified if exceeded.

### Checkpoint 3: Cross-validation strategy suited to small, imbalanced n
- [ ] Use **stratified** k-fold (or stratified leave-one-out, given n=45) so
  each fold preserves the ~27% recurrence rate. With only 12 positive cases,
  5-fold stratified CV yields just 2-3 positives per held-out fold — note this
  explicitly as a precision-of-estimate limitation.
- [ ] Consider repeated stratified k-fold (e.g., 10x5-fold) to reduce variance
  in the performance estimate and report mean ± SD across repeats, not a
  single split's result.
- [ ] If a train/test split (rather than pure CV) is used at any stage, confirm
  stratification by outcome and that the split is reported (e.g., how many
  recurrence cases fall in test vs. train).

### Checkpoint 4: Segmentation-related sources of variability
Whole-tumor masks remove sub-region heterogeneity information but still carry
methodological risks worth documenting:
- [ ] Note whether masks were manually drawn, semi-automated, or fully
  automated, and by how many raters.
- [ ] If feasible, report inter-observer agreement (e.g., Dice coefficient) on
  a subset, since radiomic features — particularly shape and texture features —
  can be sensitive to segmentation variability.
- [ ] Confirm voxel resampling / normalization (slice thickness, in-plane
  resolution) was applied consistently across patients before feature
  extraction, since whole-tumor masks from heterogeneous acquisition protocols
  can introduce scanner-driven feature variance that's easy to mistake for
  biological signal.

### Checkpoint 5: Reporting standards
- [ ] Report results following a checklist appropriate to small-cohort
  radiomics/ML studies (e.g., TRIPOD or METRICS-style reporting) so that the
  n=45 (12/33) cohort size and its implications for generalizability are
  transparent to readers.
- [ ] Explicitly state that, given n=45, any performance estimate should be
  accompanied by a confidence interval (e.g., bootstrap CI) rather than a
  point estimate alone.
- [ ] Flag that external validation on an independent cohort is needed before
  any claims of clinical utility — internal CV performance on 45 patients is a
  preliminary signal, not a validated model.
```

A few things I deliberately left as checkboxes rather than filled-in answers, because I don't have visibility into your actual notebook/pipeline and don't want to assert something that isn't true of your setup:

- **What features you're extracting** (radiomics package, number of features, whether shape/texture/first-order are all included) — I don't know this, so Checkpoint 2's feature-count guidance is generic. Fill in the actual number so the "features per event" ratio can be checked concretely.
- **Your actual CV scheme** (currently implemented) — I don't know if you're already doing stratified k-fold, LOOCV, or a single holdout split. The checklist assumes you'll confirm which one applies and check the corresponding box.
- **How the masks were generated** (manual/automated, single vs. multiple raters) — I don't have this information from what you've told me, so I left it as something for you to document rather than assuming a specific workflow.
- **Imaging modality and acquisition protocol** — you didn't specify MRI vs. CT vs. another modality, or whether this is single-institution/single-scanner data, which affects how much weight to put on the harmonization checkpoint. If it's single-scanner, that checkpoint is less critical; if multi-site, I'd elevate it.

If you let me know your feature count, CV approach, and segmentation provenance, I can fill in the checkboxes with concrete pass/fail statements instead of leaving them as open items.
